At the news
? BEARISHIMPACT 7/10 S-3 filed Mar 20, 2026 at 17:00 ET
InMed Pharmaceuticals has filed an S-3 shelf registration statement allowing it to raise up to $50 million through future offerings of common shares, preferred shares, warrants, subscription rights, or units. This signals a potential capital raise, which could lead to significant shareholder dilution given the company's current $2 million market cap. The filing comes amid ongoing operating losses and substantial doubt about the company's ability to continue as a going concern, particularly due to adverse U.S. legislation impacting its BayMedica commercial business.
- InMed filed an S-3 shelf registration allowing for up to $50 million in future securities offerings.
- The company's market cap is only $2 million, meaning the offering could result in massive dilution of up to 2,500%.
- InMed has recurring operating losses and an accumulated deficit, with auditors noting substantial doubt about its ability to continue as a going concern.
- The company's BayMedica commercial business faces material adverse impact from recent U.S. legislation affecting its cannabinoid inventory.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access